Search

Displaying results 8621 - 8630 of 10000 in total
  1. Drug

    Ergidina

    go.drugbank.com/drugs/DB18565
    Experimental

    Ergidina is a recombinant human minibody against complement component C5 fused with RGD-motif.

    Synonyms: Neutralizing scFv dimer to C5 fused at the C terminal end to the Fc domains of human IgG1 and the cyclic RGD-4C peptide (ACDCRGDCFCG)
  2. Drug

    AB-G023

    go.drugbank.com/drugs/DB18576
    Experimental

    AB-G023 is a solution stable glucagon analog

  3. Drug

    PBGM01

    go.drugbank.com/drugs/DB18581
    Investigational

    PBGM01 is a non-replicating recombinant adeno-associated virus serotype hu68 vector, which contains human GLB1 transgene encoding the galactosidase beta 1 enzyme.

  4. Drug

    CTR-107

    go.drugbank.com/drugs/DB18583
    Experimental

    CTR-107 is a synthetic targeted growth factor. It is being investigated for the treatment of familial exudative vitreoretinopathy.

  5. Drug

    Zelpultide alfa

    go.drugbank.com/drugs/DB18587
    Investigational

    Zelpultide alfa is a recombinant human surfactant protein D.

    Synonyms: HUMAN PULMONARY SURFACTANT-ASSOCIATED PROTEIN D (PSPD, SURFACTANT PROTEIN D, SP-D, COLLECTIN-7, SURFACTANT PROTEIN D), NON-COVALENT QUADRUPLE TRIMER, PRODUCED IN HUMAN MYELOGENOUS LEUKEMIA K562 CELLS,, RECOMBINANT SP-D
  6. Drug

    FCR001

    go.drugbank.com/drugs/DB18595
    Investigational

    FCR001 is a somatic cell therapy product containing hematopoietic progenitor cells (HPC), Facilitating Cells (FC), and alpha beta T cells.

  7. Drug

    Sulfobutylether-beta-cyclodextrin

    go.drugbank.com/drugs/DB18607
    Experimental

    Categories: Compounds used in a research, industrial, or household setting
  8. Drug

    Sapablursen

    go.drugbank.com/drugs/DB18608
    Investigational

    Sapablursen is a synthetic 2'-O-(2-methoxyethyl)-modified antisense oligonucleotide linked to a tri-antennary cluster of N-acetyl galactosamine (GalNAc3) sugars targeting transmembrane protease, serine … 6 messenger ribonucleic acid

  9. Drug

    PAS-004

    go.drugbank.com/drugs/DB18611
    Investigational

    PAS-004 is an allosteric MEK 1/2 inhibitor being developed by Pasithea Therapeutics. It is being investigated for the treatment of neurofibromatosis 1 and Noonan syndrome.

  10. Drug

    AAV9/MFSD8

    go.drugbank.com/drugs/DB18616
    Experimental

    AAV9/MFSD8 is a gene therapy developed by Neurogene Inc. … It was investigated for the treatment of neuronal ceroid lipofuscinosis type 7.

    Synonyms: An adeno-associated virus serotype 9 (AAV9) vector with engineered transgene encoding the human CLN7/MFSD8 gene for expression of active human major facilitator superfamily domain containing 8